Home Sweet Home: Adarza Settles into New Facility
Agreement gives Horizon exclusive right to supply services on Ardaza’s multiplex label-free immunoassay technology.
St. Louis Business Journal: St. Louis biotech startup to launch products in 2019
Once Adarza's products launch in the second quarter of 2019, it will be one of a handful of local life sciences startups to have done so.
Adarza Sets Stage for Commercialization
Adarza Biosystems, Inc., a biotechnology company developing a novel protein and biomolecule detection platform, announced today that it has put in place the leadership, new manufacturing center and branding to begin selling its technology to researchers in the second quarter of 2019.
St. Louis Post-Dispatch: As Adarza scales up, St. Louis hopes for an important win
As Adarza scales up, St. Louis hopes for an important win. By David Nicklaus
St. Louis Business Journal: RiverVest leads $17M investment in Adarza, brings on new president
RiverVest leads $17 million investment in Adarza, brings on new president
ADARZA BIOSYSTEMS CLOSES ON $17 MILLION SERIES C FINANCING
ROCHESTER, NY and ST LOUIS, MO (Jan. 19, 2017) – Adarza BioSystems, Inc., a leading next generation innovator in label-free, multiplex assays, announced today that it has closed a $17M Series C financing. Proceeds from the financing will be used to further expand production capacity in its St. Peters, MO manufacturing facility and fund final development and commercialization of Adarza’s first immunoassay product consumable and instrument platform. Adarza develops and manufactures immunoassay technology that can identify proteins and genetic markers in medical samples such as blood. The technology, which comes in the form of microchips, [...]
Event Update
Join us at the 15th Cytokines & Inflammation Conference, February 6-7, 2017 in San Diego, CA. Booth #6. And check our poster while you’re there: “A Multiplex Panel for Simultaneously Profiling Toxicant Levels and Biological Response Indicators in Serum Samples”.
Senior QC Manager
Adarza BioSystems, Inc. is a venture capital backed biotechnology company developing label-free protein microarray assays based on the Company’s proprietary Arrayed Imaging Reflectometry (AIR™) platform. Adarza is seeking a Quality Manager to implement our QMS and lead the ISO 9001:2015 certification process. Reporting to the Head of Missouri Operations, this individual will have an opportunity to develop and grow with a dynamic, emerging company in the greater St. Louis, MO area. Job Description: The position requires proven expertise in creating and maintaining a Quality Management system, starting with the Quality Policy and then translating [...]
Adarza BioSystems Completes $5 M Series-B Closing
ROCHESTER, N.Y. ST LOUIS, MO – Adarza BioSystems, Inc. a leading next generation innovator in label-free, multiplex assays announced today that it has closed a $5 M Series B financing. Proceeds from the financing will be used to expand production capacity in its St. Peters, MO manufacturing facility and launch its first immunoassay product consumable and instrument platform. Proceeds will also be used to accelerate development of highly sensitive assays targeting a variety of biological analytes including cytokines, antigens and small molecules. Adarza’s Arrayed Imaging Reflectometry (AIRstrip™) will bring an unprecedented combination of performance, [...]
Horizon Discovery Group plc and Adarza BioSystems Enter Supply & Licensing Agreement
Agreement gives Horizon exclusive right to supply services on Ardaza’s multiplex label-free immunoassay technology.